{"id":"https://openalex.org/W7223701673","doi":"https://doi.org/10.3389/fonc.2026.1981577","title":"Primary resistance to afatinib in a patient with NSCLC harboring EGFR p.E709_T710delinsD and brain metastases: a case report and literature review","display_name":"Primary resistance to afatinib in a patient with NSCLC harboring EGFR p.E709_T710delinsD and brain metastases: a case report and literature review","publication_year":2026,"publication_date":"2026-10-26","ids":{"openalex":"https://openalex.org/W7223701673","doi":"https://doi.org/10.3389/fonc.2026.1981577"},"language":"en","primary_location":{"id":"doi:10.3389/fonc.2026.1981577","doi":"https://doi.org/10.3389/fonc.2026.1981577","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fonc.2026.1981577","pdf_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1981577/pdf","source":{"id":"https://openalex.org/S2596394214","display_name":"Frontiers in Oncology","issn_l":"2234-943X","issn":["2234-943X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1981577/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5104281834","display_name":"Su-Su Dong","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I139660479","display_name":"Central South University","ror":"https://ror.org/00f1zfq44","country_code":"CN","type":"education","lineage":["https://openalex.org/I139660479"]},{"id":"https://openalex.org/I4210123733","display_name":"The First People's Hospital of Changde","ror":"https://ror.org/02h2ywm64","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210123733"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Su-Su Dong","raw_affiliation_strings":["Department of Respiratory Medicine, Changde Hospital, Xiangya School of Medicine, Central South University (The First People\u2019s Hospital of Changde City)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Respiratory Medicine, Changde Hospital, Xiangya School of Medicine, Central South University (The First People\u2019s Hospital of Changde City)","institution_ids":["https://openalex.org/I139660479","https://openalex.org/I4210123733"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100306427","display_name":"Xuan Zhang","orcid":"https://orcid.org/0009-0004-1480-2503","observed_orcids":["https://orcid.org/0009-0004-1480-2503"]},"institutions":[{"id":"https://openalex.org/I139660479","display_name":"Central South University","ror":"https://ror.org/00f1zfq44","country_code":"CN","type":"education","lineage":["https://openalex.org/I139660479"]},{"id":"https://openalex.org/I4210123733","display_name":"The First People's Hospital of Changde","ror":"https://ror.org/02h2ywm64","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210123733"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Xuan Zhang","raw_affiliation_strings":["Department of Respiratory Medicine, Changde Hospital, Xiangya School of Medicine, Central South University (The First People\u2019s Hospital of Changde City)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Respiratory Medicine, Changde Hospital, Xiangya School of Medicine, Central South University (The First People\u2019s Hospital of Changde City)","institution_ids":["https://openalex.org/I139660479","https://openalex.org/I4210123733"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5049959591","display_name":"Wen Dong","orcid":"https://orcid.org/0000-0003-3955-4062","observed_orcids":["https://orcid.org/0000-0003-3955-4062"]},"institutions":[{"id":"https://openalex.org/I139660479","display_name":"Central South University","ror":"https://ror.org/00f1zfq44","country_code":"CN","type":"education","lineage":["https://openalex.org/I139660479"]},{"id":"https://openalex.org/I4210123733","display_name":"The First People's Hospital of Changde","ror":"https://ror.org/02h2ywm64","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210123733"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Wen Dong","raw_affiliation_strings":["Department of Oncology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People\u2019s Hospital of Changde City)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People\u2019s Hospital of Changde City)","institution_ids":["https://openalex.org/I139660479","https://openalex.org/I4210123733"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5100306427"],"corresponding_institution_ids":["https://openalex.org/I139660479","https://openalex.org/I4210123733"],"apc_list":{"value":3150,"currency":"CHF","value_usd":3801},"apc_paid":{"value":3150,"currency":"CHF","value_usd":3801},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.86686873,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"16","issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/afatinib","display_name":"afatinib","score":0.8989999890327454},{"id":"https://openalex.org/keywords/primary-drug-resistance","display_name":"primary drug resistance","score":0.8730000257492065},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.8809999823570251},{"id":"https://openalex.org/keywords/lung-adenocarcinoma","display_name":"lung adenocarcinoma","score":0.9660000205039978},{"id":"https://openalex.org/keywords/brain-metastases","display_name":"brain metastases","score":0.9430000185966492},{"id":"https://openalex.org/keywords/egfr-amplification","display_name":"EGFR amplification","score":0.9670000076293945},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.5649999976158142},{"id":"https://openalex.org/keywords/disease-progression","display_name":"disease progression","score":0.6330000162124634},{"id":"https://openalex.org/keywords/circulating-tumor-dna","display_name":"circulating tumor DNA","score":0.8669999837875366},{"id":"https://openalex.org/keywords/resistance-mechanisms","display_name":"resistance mechanisms","score":0.6140000224113464}],"concepts":[{"id":"https://openalex.org/C2780586478","wikidata":"https://www.wikidata.org/wiki/Q4688818","display_name":"Afatinib","level":5,"score":0.9779999852180481},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8522999882698059},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6133999824523926},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.6028000116348267},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.5220000147819519},{"id":"https://openalex.org/C2781182431","wikidata":"https://www.wikidata.org/wiki/Q356033","display_name":"Adenocarcinoma","level":3,"score":0.5218999981880188},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4742000102996826},{"id":"https://openalex.org/C501734568","wikidata":"https://www.wikidata.org/wiki/Q42918","display_name":"Mutation","level":3,"score":0.45210000872612},{"id":"https://openalex.org/C2780283643","wikidata":"https://www.wikidata.org/wiki/Q2110267","display_name":"Primary tumor","level":4,"score":0.4514999985694885},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4259999990463257},{"id":"https://openalex.org/C2775934546","wikidata":"https://www.wikidata.org/wiki/Q179991","display_name":"Biopsy","level":2,"score":0.4059000015258789},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3937000036239624},{"id":"https://openalex.org/C2779529041","wikidata":"https://www.wikidata.org/wiki/Q22349364","display_name":"Liquid biopsy","level":3,"score":0.38760000467300415},{"id":"https://openalex.org/C36823959","wikidata":"https://www.wikidata.org/wiki/Q373027","display_name":"Exon","level":3,"score":0.382099986076355},{"id":"https://openalex.org/C146357865","wikidata":"https://www.wikidata.org/wiki/Q1123245","display_name":"Stage (stratigraphy)","level":2,"score":0.38089999556541443},{"id":"https://openalex.org/C2777714996","wikidata":"https://www.wikidata.org/wiki/Q7886","display_name":"Lung","level":2,"score":0.3788999915122986},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.35910001397132874},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.35690000653266907},{"id":"https://openalex.org/C2777930144","wikidata":"https://www.wikidata.org/wiki/Q25100112","display_name":"T790M","level":5,"score":0.3481000065803528},{"id":"https://openalex.org/C2994294914","wikidata":"https://www.wikidata.org/wiki/Q1645075","display_name":"Acquired resistance","level":3,"score":0.34049999713897705},{"id":"https://openalex.org/C114851261","wikidata":"https://www.wikidata.org/wiki/Q12147416","display_name":"Drug resistance","level":2,"score":0.3382999897003174},{"id":"https://openalex.org/C182707283","wikidata":"https://www.wikidata.org/wiki/Q7315622","display_name":"Resistance mutation","level":5,"score":0.32100000977516174},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.31470000743865967},{"id":"https://openalex.org/C89611455","wikidata":"https://www.wikidata.org/wiki/Q6804646","display_name":"Mechanism (biology)","level":2,"score":0.3066999912261963},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.29789999127388},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.29409998655319214},{"id":"https://openalex.org/C2777546739","wikidata":"https://www.wikidata.org/wiki/Q33525","display_name":"Carcinoma","level":2,"score":0.28459998965263367},{"id":"https://openalex.org/C2777506169","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"EGFR inhibitors","level":4,"score":0.27720001339912415},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.26159998774528503},{"id":"https://openalex.org/C180754005","wikidata":"https://www.wikidata.org/wiki/Q80726","display_name":"Allele","level":3,"score":0.2615000009536743},{"id":"https://openalex.org/C2781187634","wikidata":"https://www.wikidata.org/wiki/Q20969980","display_name":"KRAS","level":4,"score":0.2605000138282776},{"id":"https://openalex.org/C61238886","wikidata":"https://www.wikidata.org/wiki/Q5121689","display_name":"Circulating tumor cell","level":4,"score":0.2599000036716461}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.3389/fonc.2026.1981577","doi":"https://doi.org/10.3389/fonc.2026.1981577","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fonc.2026.1981577","pdf_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1981577/pdf","source":{"id":"https://openalex.org/S2596394214","display_name":"Frontiers in Oncology","issn_l":"2234-943X","issn":["2234-943X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Oncology","raw_type":"journal-article"},{"id":"pmh:oai:doaj.org/article:a3c73ebf02f7442a8dfcd0f8b3b04a2d","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/a3c73ebf02f7442a8dfcd0f8b3b04a2d","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Oncology, Vol 16 (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3389/fonc.2026.1981577","doi":"https://doi.org/10.3389/fonc.2026.1981577","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fonc.2026.1981577","pdf_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1981577/pdf","source":{"id":"https://openalex.org/S2596394214","display_name":"Frontiers in Oncology","issn_l":"2234-943X","issn":["2234-943X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Case Report","id":"https://openalex.org/study-designs/case-report"}],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7223701673.pdf","grobid_xml":"https://content.openalex.org/works/W7223701673.grobid-xml"},"referenced_works_count":29,"referenced_works":["https://openalex.org/W1853526923","https://openalex.org/W2010683747","https://openalex.org/W2043826980","https://openalex.org/W2131323155","https://openalex.org/W2283037401","https://openalex.org/W2530772402","https://openalex.org/W2594832304","https://openalex.org/W2753391559","https://openalex.org/W2803544184","https://openalex.org/W2899917279","https://openalex.org/W2902180784","https://openalex.org/W2917596286","https://openalex.org/W2944206462","https://openalex.org/W2950119923","https://openalex.org/W2975733910","https://openalex.org/W2985129672","https://openalex.org/W3007474453","https://openalex.org/W3169975926","https://openalex.org/W3172027020","https://openalex.org/W3189246448","https://openalex.org/W3200033087","https://openalex.org/W4281761928","https://openalex.org/W4284884517","https://openalex.org/W4366601849","https://openalex.org/W4393031564","https://openalex.org/W4401584893","https://openalex.org/W4414795299","https://openalex.org/W7126209438","https://openalex.org/W7162548605"],"related_works":["https://openalex.org/W2975733910","https://openalex.org/W3172027020","https://openalex.org/W2803544184","https://openalex.org/W4292978336","https://openalex.org/W2950119923","https://openalex.org/W92334305","https://openalex.org/W2032712631","https://openalex.org/W2896143218","https://openalex.org/W2766770215","https://openalex.org/W7164885348"],"abstract_inverted_index":{"EGFR":[0,14,60,69,131],"p.E709_T710delinsD":[1,61,132],"is":[2,44],"a":[3,49,115,200],"rare":[4,116],"in-frame":[5],"deletion-insertion":[6],"P-loop":[7],"and":[8,139,164,191,206,220,242],"alpha-C-helix":[9],"compressing":[10],"(PACC)":[11],"mutation":[12,62],"of":[13,91,118,137,176],"exon":[15],"18.":[16],"Current":[17],"evidence":[18,141],"suggests":[19,182],"that":[20,183],"patients":[21,185],"with":[22,53,67,84,161,186,202],"non-small":[23,124],"cell":[24,125],"lung":[25,56,126],"cancer":[26,127],"(NSCLC)":[27,128],"harboring":[28,58,129],"this":[29,41,148,150,177,195],"variant":[30,178,196],"generally":[31],"respond":[32],"to":[33,38,121,142,155,179,237],"afatinib.":[34],"However,":[35],"primary":[36,103,119],"resistance":[37,120,145,240],"afatinib":[39,86,122],"in":[40,123,147,184],"molecular":[42,140],"subset":[43],"rarely":[45],"reported.":[46],"We":[47],"report":[48,151],"68-year-old":[50],"man":[51],"diagnosed":[52],"stage":[54],"IV":[55],"adenocarcinoma":[57],"an":[59,88],"(variant":[63],"allele":[64],"frequency,":[65],"45.9%)":[66],"co-occurring":[68],"amplification":[70],"(fold":[71],"change":[72],"1.5).":[73],"Brain":[74],"metastases":[75],"were":[76],"present":[77,198],"at":[78,87],"baseline.":[79],"The":[80,106],"patient":[81,107],"was":[82],"treated":[83],"oral":[85],"initial":[89,204],"dose":[90],"30":[92],"mg":[93],"once":[94],"daily":[95],"but":[96,181],"the":[97,130,135,144,157,173,239],"disease":[98,189],"progressed":[99],"rapidly,":[100],"suggesting":[101],"possible":[102],"targeted":[104],"resistance.":[105],"died":[108],"5":[109],"weeks":[110],"later.":[111],"This":[112,168],"case":[113,169],"represents":[114],"example":[117],"mutation.":[133],"Given":[134],"lack":[136],"tissue":[138],"confirm":[143],"mechanism":[146,241],"case,":[149],"combines":[152],"previous":[153],"literature":[154],"explore":[156],"potential":[158],"factors":[159],"associated":[160],"treatment":[162],"failure":[163],"their":[165],"clinical":[166],"implications.":[167],"does":[170],"not":[171],"refute":[172],"overall":[174],"sensitivity":[175],"afatinib,":[180],"high":[187],"baseline":[188],"burden":[190],"aggressive":[192],"tumor":[193,225],"biology,":[194],"may":[197],"as":[199,232,234],"phenotype":[201],"no":[203],"benefit":[205],"rapid":[207],"progression.":[208],"For":[209],"such":[210],"rapidly":[211],"progressive":[212],"cases,":[213],"early":[214],"radiographic":[215],"reassessment":[216],"should":[217,229],"be":[218,230],"performed,":[219],"repeat":[221],"biopsy":[222],"or":[223],"circulating":[224],"DNA":[226],"(ctDNA)":[227],"testing":[228],"pursued":[231],"soon":[233],"safely":[235],"feasible":[236],"clarify":[238],"guide":[243],"subsequent":[244],"treatment.":[245]},"counts_by_year":[],"updated_date":"2026-10-29T09:56:32.521200","created_date":"2026-10-27T00:00:00"}